ValuEngine Downgrades Humanigen (OTCMKTS:HGEN) to Hold

Humanigen (OTCMKTS:HGEN) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, July 24th, ValuEngine reports.

Shares of OTCMKTS HGEN remained flat at $$1.00 during midday trading on Wednesday. The firm has a fifty day moving average of $1.03 and a 200 day moving average of $1.18. Humanigen has a 1-year low of $0.45 and a 1-year high of $1.54.

About Humanigen

Humanigen, Inc, a biopharmaceutical company, engages in developing its proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's products include lenzilumab and ifabotuzumab, which are monoclonal antibodies derived from Humaneered platform. Lenzilumab targets granulocyte-macrophage colony-stimulating factor (GM-CSF), and is in development as a potential medicine for chimeric antigen receptor T cell (CAR-T) therapy, as well as a potential treatment for rare hematologic cancers, such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML).

Further Reading: Hold Rating

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Humanigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen and related companies with MarketBeat.com's FREE daily email newsletter.